Machine learning models classify the likelihood of developing Alzheimer's.

Published Date: 05 Apr 2023

A new study suggests that once adults reach age 65, the cutoff age for Alzheimer's disease onset, the extent of their genetic risk may outweigh age as a predictor of whether they will experience the fatal brain disorder.

Read Full News

Latest News

Anxiety and Depression May Raise Risk for Aneurysm Rupture

Anxiety and depression are linked to an increased risk for rupture and mortality in patients with unruptured intracranial aneurysms, a new cohort study shows.

China Approves Market Launch Of Brain-computer Interface Medical Device in World First

China's drug regulator said on Friday that it has given the nod for a brain-computer interface (BCI) system ⁠that helps restore hand-movement ability to be sold, the world's...

Why Aren’t Canadians Getting Enough Sleep?

The change to daylight saving time and the marking of World Sleep Day call attention to the factors that contribute to sleep deficits among Canadians.

Single IV Ketamine Promising for Depression in MCI

Ketamine is well-tolerated in older adults with both mild cognitive impairment and depression and associated with improved depression scores, a new study shows.

Late Complications Common After CVT, Even After Recovery

Although a majority of patients with cerebral venous sinus thrombosis achieve independence, 1 in 3 may develop delayed complications such as seizures, a study shows.

Activity Trackers May Predict MS Progression

Reduced daytime physical activity, as measured with wearable trackers, is tied to increased risk for multiple sclerosis progression and brain atrophy, new research shows.

Todays Updates

Older Adults With Advanced Cancer Prioritize Quality of Life

Most older adults with advanced cancer value quality of life over extending survival, but that preference may not translate to clinical care or outcomes.

Todays Updates

Older Adults With Advanced Cancer Prioritize Quality of Life

Most older adults with advanced cancer value quality of life over extending survival, but that preference may not translate to clinical care or outcomes.

Latest News

Anxiety and depression are linked to an increased risk for rupture and mortality in patients with unruptured intracranial aneurysms, a new cohort study shows.

China's drug regulator said on Friday that it has given the nod for a brain-computer interface (BCI) system ⁠that helps restore hand-movement ability to be sold, the world's...

The change to daylight saving time and the marking of World Sleep Day call attention to the factors that contribute to sleep deficits among Canadians.

Ketamine is well-tolerated in older adults with both mild cognitive impairment and depression and associated with improved depression scores, a new study shows.

Although a majority of patients with cerebral venous sinus thrombosis achieve independence, 1 in 3 may develop delayed complications such as seizures, a study shows.

Reduced daytime physical activity, as measured with wearable trackers, is tied to increased risk for multiple sclerosis progression and brain atrophy, new research shows.

News All Time

Fertility Treatments Linked to Higher Med Use in Offspring

Children conceived through medically assisted reproduction have higher out-of-hospital healthcare utilization including mental health medications.

Lifetime Risk Estimates for Dementia, MCI: New Data

Mild cognitive impairment before dementia is common in older adults, with women facing a higher lifetime burden and Black adults an earlier onset, new research shows.

Fibromyalgia-PTSD Link Shows Bidirectional Relationship

Research suggests a bidirectional relationship between posttraumatic stress disorder and fibromyalgia in military service members exposed to combat environments.

Trials Offer Mixed Results on BTK Potential for PPMS

Promising findings for fenebrutinib and disappointing results for tolebrutinib offer mixed results on the potential of BTK inhibitors for primary progressive MS.

Redefining Cognitive Assessment With One Blood Test

Blood p-tau217 testing in real-world practice enhances diagnostic accuracy and neurologists' diagnostic confidence, with the greatest diagnostic shifts seen in mild cognitive impairment and dementia.

What If We’ve Been Wrong About How ADHD Drugs Work?

A new analysis of brain scans from nearly 12,000 children could change the way clinicians and researchers think about how stimulants for ADHD work.

Wrist-Worn Sleep Trackers Predict Depression Relapse

Actigraphy data show irregular sleep-wake rhythms nearly double the risk for relapse in individuals with remitted major depressive disorder.

Japan Endorses IPS-derived Treatment for Parkinson's

A panel of specialists has endorsed an iPS cell-derived treatment for Parkinson's ⁠disease, paving the ‌way for the world's first medical products based on the technology.

Vertebral Fractures Tied to Lower Lung Volumes in ILD

Thoracic vertebral fractures may worsen lung function and reduce lung volumes in patients with interstitial lung disease.

Cognitive Training May Lower Dementia Risk 20 Years Later

In a long-running RCT, older adults who completed adaptive speed-of-processing training with boosters were less likely to develop dementia — a benefit not seen with memory or reasoning training.

Lifelong Cognitive Enrichment Tied to Lower Dementia Risk

Lifelong cognitive enrichment is linked to a lower risk for Alzheimer's disease, delayed onset, and better cognitive function despite brain pathology.

FDA Okays Pitolisant for Cataplexy in Pediatric Narcolepsy

With this new indication, pitolisant is now approved to treat excessive daytime sleepiness, cataplexy, or both, in patients aged 6 years or older with narcolepsy.

NeuroVoices: Katrina Bawden, MSN, MSCN, FNP-C, on Emerging Therapies and Women’s Health Priorities in Multiple Sclerosis Katrina Bawden, MSN, MSCN, FNP-C

A nurse practitioner at the Rocky Mountain MS Clinic discussed emerging therapeutics, evolving management strategies, and unmet needs in multiple sclerosis, specifically in women’s health.

FDA Accepts New Drug Application for Orexin Agonist Oveporexton in Narcolepsy Type 1, Grants Priority Review Isabella Ciccone, MPH

The FDA has granted priority review to Takeda’s new drug application for oveporexton, an orexin receptor 2-selective agonist, for narcolepsy type 1, with a PDUFA date in the third quarter of 2026.

NeurologyLive® Brain Games: February 8, 2026 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on diagnosing parasomnias!

Remelyinating Drug Bazedoxifene Fails to Meet End Points in Phase 2 Study of Multiple Sclerosis Louie Pasculli

Late-breaking data from the 2026 ACTRIMS Forum showed that bazedoxifene acetate failed to improve remyelination outcomes in midlife women with relapsing MS, despite a favorable safety profile.